Printer Friendly

Articles from M2 Pharma (October 11, 2018)

1-22 out of 22 article(s)
Title Author Type Words
Allogene Therapeutics Prices USD 324m US Initial Public Offering. 200
Bristol-Myers Squibb, Compugen Forge Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors. 704
Carrick Therapeutics in-licenses targeted ovarian cancer treatment CT900 plus announces new chairman. 275
First clinical trial of Alzheimer's disease treatment starts at The National Institute for Health Research University College London Hospitals Clinical Research Facility. 208
Inceptua Group names Maria Eklind-Cervenka as CMO. 102
Inceptua names new chief medical officer. 145
Intellectual Property Protection for Tetra Discovery Partners' BPN14770 Boosted with Issuance of New US Patent. 341
International Clinical Trial Utilises Personal Genome Diagnostics' Liquid Biopsy Assay to Enroll Patients based on POLE/POLD1 status as a Predictor of Response to Immunotherapy. 271
Janssen Pharmaceutical's Stelara single dose succeeds in phase three ulcerative colitis study. 264
Kodiak Sciences Inc concludes IPO at USD10.00 per share. 126
MinuteClinic announces new Louisiana virtual health care offering. 222
Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR annual meeting. 350
Neovasc awarded US FDA's breakthrough device designation for the Neovasc Reducer. 197
Neurocrine Biosciences signs research collaboration with Jnana Therapeutics. 134
Otsuka partners with Proteus Digital Health to advance digital medicines in mental health. 236
PharmaCyte Biotech PCT Patent Application for Cancer Therapies Published. 600
Rgenix Raises USD 40m in Series C Funding To Support Clinical Stage Oncology Programs. 436
SpineEX wins US FDA's clearance for Sagittae lateral lumbar Interbody fusion device. 277
Synspira Receives US FDA Orphan Designation for PAAG15A for the Treatment of Cystic Fibrosis. 478
Themis Bioscience Inks Exclusive Licensing Agreement with Max-Planck-Innovation to Develop and Commercialise Oncolytic Virotherapies. 361
Themis Bioscience signs exclusive licensing agreement with Max-Planck-Innovation for oncolytic virotherapies. 287
WellSky and Digi-Trax Partner to Power Safer, More Efficient Cellular Therapy Management. 299

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters